Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antithrombotic therapy for secondary prevention in patients with acute coronary syndromes treated with percutaneous coronary intervention: options for personalization to reduce bleeding or ischaemic risks. A Clinical Consensus Statement of the ESC Working Group on Thrombosis, the Association for Acute CardioVascular Care of the ESC, the European Association of Percutaneous Cardiovascular Interventions of the ESC, and the ESC Working Group on Cardiovascular Pharmacology A Clinical Consensus Statement of the ESC Working Group on Thrombosis, the Association for Acute CardioVascular Care of the ESC, the European Association of Percutaneous Cardiovascular Interventions of the ESC, and the ESC Working Group on Cardiovascular Pharmacology.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·2026
Same author

Advances in Clinical Cardiology 2025: A Summary of Key Clinical Trials.

Advances in therapy·2026
Same author

Impact of Revascularization Completeness on Cardiovascular Outcomes in STEMI With Multivessel Disease.

Circulation. Cardiovascular interventions·2026
Same author

Stent thrombosis associated with non-response to clopidogrel despite co-administration of aspirin and ibrutinib.

European heart journal. Case reports·2026
Same author

Invasive vs Conservative Strategy for Frail Older Patients With Myocardial Infarction: A Secondary Analysis of the SENIOR-RITA Randomized Clinical Trial.

JAMA network open·2026
Same author

Prognostic Value of Impaired Spirometry in Patients with Myocardial Infarction: A Longitudinal Study of Two European Cohorts.

International journal of chronic obstructive pulmonary disease·2026
Same journal

Time-dependent prognostic performance of inflammatory biomarkers after AMI: results from the INFINITY study.

Biomarkers in medicine·2026
Same journal

Serial sST2 dynamics after transcatheter tricuspid valve intervention: a candidate biomarker of biological response.

Biomarkers in medicine·2026
Same journal

Prognostic value of blood urea nitrogen-creatinine ratio for rehospitalization and outcomes in myocardial infarction: a four-year retrospective cohort analysis.

Biomarkers in medicine·2026
Same journal

Dietary glycemic index/glycemic load and knee osteoarthritis: associations with inflammation and oxidative stress.

Biomarkers in medicine·2026
Same journal

Prognostic value of the CALLY index in patients undergoing transcatheter aortic valve implantation.

Biomarkers in medicine·2026
Same journal

The relationship between serum neopterin levels and disease activity in patients with spondyloarthropathy.

Biomarkers in medicine·2026
See all related articles

Related Experiment Video

Updated: Jun 4, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Ticagrelor: from concept to clinical evaluation.

James A Shand1, Ian B A Menown, Robert F Storey

  • 1Craigavon Cardiac Centre, Southern Trust, Craigavon, Northern Ireland, UK.

Biomarkers in Medicine
|February 16, 2011
PubMed
Summary
This summary is machine-generated.

Ticagrelor offers faster and more consistent platelet inhibition than clopidogrel for acute coronary syndrome patients. This improved antiplatelet therapy significantly reduces major adverse cardiovascular events.

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Related Experiment Videos

Last Updated: Jun 4, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor blocker is standard for acute coronary syndromes (ACS) and percutaneous coronary intervention (PCI).
  • Clopidogrel, a common P2Y12 inhibitor, has limitations including slow onset, variable platelet inhibition, and suboptimal maximal effect.

Purpose of the Study:

  • To evaluate the pharmacokinetic and pharmacodynamic properties of ticagrelor, a novel P2Y12 receptor blocker.
  • To compare ticagrelor's efficacy and safety against clopidogrel in patients with ACS.

Main Methods:

  • Phase II pharmacokinetic and pharmacodynamic studies of ticagrelor.
  • Analysis of data from the large-scale Platelet Inhibition and Patient Outcomes (PLATO) trial (n=18,624).

Main Results:

  • Ticagrelor demonstrated faster onset and offset of action, greater maximal platelet inhibition, and less variability compared to clopidogrel.
  • The PLATO trial showed ticagrelor reduced the primary composite endpoint (cardiovascular death, myocardial infarction, stroke) by 16% versus clopidogrel at 12 months (9.8% vs 11.7%).

Conclusions:

  • Ticagrelor offers superior pharmacokinetic and pharmacodynamic advantages over clopidogrel for antiplatelet therapy.
  • Ticagrelor significantly reduces major adverse cardiovascular events in ACS patients, supporting its role in DAPT.